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West Nile Virus (WNV) is an emerging flavivirus maintained in nature in an enzootic 
cycle between mosquitoes of the genus Culex and birds. Humans are infected mainly by 
the bites of infected mosquitoes, although other routes of transmission such as blood 
transfusion and organ transplantation have been reported (Iwamoto et al. 2003). WNV 
is commonly found in Africa,Europe, the Middle East, North America and West Asia. 
Serological studies suggest that WNV may have circulated in Europe earlier than the 
first documented outbreak inFrance in 1962. Since then, a number of human outbreaks 
have been described in European countries over the last two decades (Zeller et al. 
2004). Greece and Italy have reported human WNV infections for the last three and five 
consecutive years respectively (ECDC 2013). In Spain, early studies 
using hemaglutinin inhibition techniques suggested that WNV or closely 
related flaviviruses circulated in some parts of the country during the 1970’s (Gonzalez 
et al. 1977; Lozano et al. 1998). Clear evidence of WNV activity in Spain has been 
accumulating since the year 2000, including detection of neutralizing antibodies in 
birds, horses, detection of WNV RNA and virus isolation in eagles (Jimenez-Clavero et 
al. 2010), and the description of a single human case of WNV neurologic disease in 
2004 (Kaptoul et al. 2007). In 2010, the first outbreak of WNV was reported 
in Southern Spain, affecting more than 50 horses and 2 humans with WNV neurologic 
disease (Garcia-Bocanegra et al. 2011). In Catalonia, (Northeastern Spain) three main 
wetlands that serve as breeding sites for wild birds as well as mosquito vectors are 
present (Ebro river delta, Lobregat river delta and the and the Empordà wetlands). The 
region is considered a high-risk area for WNV and other arboviruses transmission. We 
conducted a WNV seroprevalence study in Catalonia to investigate if WNV had been 
circulating to a significant extent and to provide baseline seroprevalence data for this 




Materials and Methods 
Between November 2010 and February 2011 we collected samples from blood donors 
in 14 municipalities of the 4 catalonian provinces, selected according to the proximity 
of the wetlands and to Culex mosquitoes presence (Table 1). Basic demographic 
information of the donors was collected before anonymization of the samples with study 
numbers. The samples were screened by a commercial Enzyme-
linked Immunosorbent Assay (ELISA) (Focus Diagnostics) for the presence 
of IgG antibodies against WNV. A microneutralization protocol using two-fold sample 
dilutions (1:10-1:640) and 100 TCID50 of WNV strain NY99 in Vero cells was used as 
a confirmatory assay. As only WNV lineage 1 has been detected in humans, horses and 
birds in Spain, this lineage was selected for the neutralization protocol. Serum samples 
from 800 blood donors were collected and stored frozen until testing. 
  
Results and Discussion 
The median age of the blood donors was 45 years, ranging from 18 to 69 years; 45% 
were female. Most donors (97%) were born in Spain. Fifty-two samples were positive 
and twelve showed equivocal results by ELISA. Among these samples, only one 
resulted positive in the microneutralization assay (titer 1/40), and was negative 
for IgM antibodies by capture ELISA (Diagnostics). This sole positive sample was 
obtained from a blood donor native of Pakistan, a country where WNV and 
other flaviviruses such as Japanese encephalitis or dengue circulate (Hayes et al. 1982, 
Igarashi et al. 1994, Rafique et al. 2015). Given the low neutralization titer and the 
country of origin of the donor, the serological results suggest past infection by WNV or 
a closely related flavivirus acquired not necessarily in our region. Cross reactivity with 
other flaviviruses infection or vaccination (Hogrefe et al. 2004) and even with other 
unrelated viruses (Focus Diagnostics 2011) has been reported to occur with 
WNV ELISA’s and therefore seroneutralization is needed to be performed as a 
confirmatory assay. More than 75% of the samples analyzed by neutralization showed 
low (<2) ELISA values (cut off: 1.1), whereas the sample with a neutralization titer of 
1/40 exhibited the highest ELISA value (5.7) of all samples. 
Similar WNV seroprevalence studies in blood donors have been performed in 
other European countries such as France (Charrel et al. 2001) or Italy (Pezzotti et al. 
2011, Pierro et al. 2013), detecting 0.76 and 0.78% samples with neutralizing antibodies 
respectively, although these studies were conducted in areas with previous documented 
circulation of the virus. The last WNV seroprevalence study in Catalonia was performed 
in 2001, focussing on one of the three wetlands in the region (Ebro river delta). From 
992 participants, 2 samples were positive by seroneutralization (Bofill et al. 2006). An 
ecological surveillance for WNV in Catalonia has been recently described (Alba et al. 
2014). Horses, sentinel chickens, wild birds and mosquitoes were analyzed from 2007 
to 2011. No evidence of WNV infection was found in domestic animals or mosquitoes. 
However, positive serological tests were obtained in wild birds during 2010 and2011, 
suggesting that WNV or a closely related flavivirus may have circulated in the region. 
Our seroprevalence results correlate with the absence of acute WNV infections in the 
animal surveillance and the absence of reported human cases in Catalonia. Moreover, no 
evidence of WNV infection was detected in 50 human cases of meningoencephalitis of 
unknown aetiology tested at our laboratory during the last three years(unpublished 
data). Taken together, it seems that transmission of WNV and human infections 
in Catalonia are rare. However, WNV activity has remained in Southern Spain since the 
2010 outbreak and the factors driving the emergence of WNV are not completely 
understood. Therefore, surveillance and preparedness in our region should be continued 
and strengthened. Our seroprevalence study may be useful as a baseline reference data 
for future monitoring of WNV presence in the Catalonia region. 
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Table1. Distribution of samples tested by location 
Province (wetland) Municipality Nº ofsamples
Barcelona El Prat de Llobregat 70 
(Llobregat river delta) Viladecans 70 
  Gavà 50 
  
Sant Boi 
de Llobregat 90 
Girona Sils 39 
(Empordá wetlands) Castelló d’Empúries 15 
  L’Escala 20 
  Roses 50 
Tarragona Deltebre 98 
(Ebro river delta) L’Ampolla 24 
  
Sant 
Jaume d'Enveja 44 
  Camarles 33 
  L’Aldea 63 
Lleida (none) Lleida 134 
  Total 800 
 
  
   
 
